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Abstract
Hyperammonemia is less severe in arginase 1 deficiency compared with other urea cycle defects. 
Affected patients manifest hyperargininemia and infrequent episodes of hyperammonemia. 
Patients typically suffer from neurological impairment with cortical and pyramidal tract 
deterioration, spasticity, loss of ambulation, seizures, and intellectual disability; death is less 
common than with other urea cycle disorders. In a mouse model of arginase I deficiency, the onset 
of symptoms begins with weight loss and gait instability which progresses to development of tail 
tremor with seizure-like activity; death typically occurs at about two weeks of life. Adeno-
associated viral vector gene replacement strategies result in long-term survival of mice with this 
disorder. With neonatal administration of vector, the viral copy number in the liver greatly 
declines with hepatocyte proliferation in the first 5 weeks of life. While the animals do survive, it 
is not known from a functional standpoint how well the urea cycle is functioning in the adult 
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animals that receive adeno-associated virus. In these studies we administered [1-13C] acetate to 
both littermate controls and adeno-associated virus-treated arginase 1 knockout animals and 
examined flux through the urea cycle. Circulating ammonia levels were mildly elevated in treated 
animals. Arginine and glutamine also had perturbations. Assessment thirty minutes after acetate 
administration demonstrated that ureagenesis was present in the treated knockout liver at levels as 
low at 3.3% of control animals. These studies demonstrate that only minimal levels of hepatic 
arginase activity are necessary for survival and ureagenesis in arginase deficient mice and that this 
level of activity results in control of circulating ammonia. These results may have implications for 
potential therapy in humans with arginase deficiency.
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Introduction
Urea is the major end-product of nitrogen metabolism in humans and terrestrial animals. The 
biochemical pathway required for its synthesis consists of 6 enzymes and 2 membrane 
transporters1. Deficiencies in each of these proteins, or the urea cycle defects, have been 
identified. Each genetic defect gives rise to a discrete clinical and biochemical phenotype1–2.
Arginase deficiency is an autosomal recessive distal urea cycle disorder resulting from a loss 
of arginase 1 (ARG1) activity. ARG1 deficiency typically presents in late infancy to the 
second year with a syndrome of microcephaly, spasticity, seizures, clonus, loss of 
ambulation, and failure to thrive associated with hyperargininemia3. Profound 
hyperammonemia is uncommon. Neonatal presentations are rare and often are associated 
with severe hyperammonemia4–5. Long-term therapy for arginase deficiency involves a low-
protein diet and administration of sodium benzoate and sodium or glycerol phenylbutyrate. 
These dietary and pharmaceutical interventions can partially alleviate hyperargininemia; 
however no completely effective therapy is available.
We have developed a gene therapy approach for ARG1−/− animals. Our approach uses an 
adeno-associated viral (AAV) vector expressing murine ARG1 administered intravenously 
on the second day of life6–8. We utilized AAV driven by the ubiquitously expressing 
chicken β-actin promoter/CMV enhancer (CBA) or the liver-specific promoter thyroxine 
binding globulin (TBG) resulting in hepatic expression of arginase 1. However, we observed 
a substantial loss of AAV vector genomes and consequent low levels of hepatic arginase 
activity because of frequent hepatocyte cell division during early life6, 9–10. Arginase 
activity can be detected by a colorimetric enzymatic assay resulting in the production of 
urea; however when the level of arginase expression is low, exact activity is difficult to 
quantify by this method.
The measurement of urea production via isotopic methods using metabolic tracers has had 
an important role in studying urea cycle flux in patients with defects in the urea cycle11. 
Such studies could also be employed to evaluate the efficacy of therapeutic interventions, in 
this case AAV-based hepatic gene transfer in the treatment of arginase deficiency in a 
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murine model. This would allow us to assess residual ureagenesis and define the minimal 
activity necessary for control of plasma ammonia, survival, longevity, and normal cognitive 
development7 in these animals. The kinetic approach also avoids limitations of the 
conventional enzyme assay which result from extremely low arginase activity. Furthermore 
knowing the amount of activity that is necessary for survival and urea cycle functioning in 
arginase-deficient animals may be important in planning future human interventions.
In these studies, we used mass spectrometry to monitor the in vivo synthesis of [13C] urea 
following administration of [1-13C] acetate. Hepatic mitochondria, the location of the first 
steps of ureagenesis, quickly convert labeled [1-13C] acetate to H13CO3− in the tricarboxylic 
acid cycle. Some of the metabolite then becomes substrate for carbamoyl phosphate 
synthetase yielding [13C] carbamoyl phosphate which the urea cycle converts to [13C] 
urea11. The remainder of the H13CO3− appears as 13CO2 in blood and in exhaled air. By 
measuring [13C] urea in blood of the mice, determination of the urea pool turnover is 
possible11. This method of investigation has provided us with an assessment of how well the 
urea cycle is functioning in stable adult ARG1−/− animals treated by AAV-based liver-
specific gene therapy. The purpose of this report is to present the outcomes and potential 
implications of this study.
Results
Animal Survival
Survival of animals undergoing interventions versus no therapy was performed. We 
observed no difference in survival of AAV-treated ARG1−/− mice vs. littermate controls at 
the time of study (p=0.43). Animals were euthanized at the completion of these studies. As 
expected, all untreated knockout animals perished before weaning (Figure 1) by about two 
weeks of life (p<0.0001 when compared with AAV-treated ARG1−/− mice or controls).
Liver Examination
We previously noted that AAV-treated animals were lean compared to their littermate 
controls6. We therefore compared liver weights between the groups and we found that this 
parameter, as a proportion of body weight, differed between groups with treated ARG1−/− 
livers being about 27% heavier more than that of littermate controls. AAV-treated ARG1−/− 
mice had livers that weighed 5.45 ± 0.53 grams (n=10) compared to that of littermate 
controls with 4.30 ± 0.30 grams (n=10) (p=0.00001). In addition, gross examination of liver 
showed a tan color in the AAV-treated ARG1−/− and a reddish brown color in controls 
(Figure 2A, B). The organs were soft without evidence of cirrhosis and were 
indistinguishable from controls when examined by palpation alone.
Plasma Ammonia and Biochemical Analysis
To determine in part how well the urea cycle was functioning, plasma ammonia 
concentration was measured before administration of [1-13C] acetate at time 0. Mice were 
studied at 10–12 weeks of age. Baseline plasma ammonia concentration did differ between 
the two groups with AAV-treated ARG1−/− mice having circulating ammonia levels about 
85% higher than that of littermate controls. Littermate controls (n=10) had plasma ammonia 
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concentrations on average of 104.03 ± 46.27 µmol/L while plasma ammonia concentrations 
in AAV-treated knockout mice (n=9) were 192.35 ± 82.12 µmol/L (p=0.01) (Figure 3).
We also noted changes in amino acids levels before and after acetate administration (Table 
1). AAV-treated ARG1−/− mice showed higher levels of plasma glutamine at baseline, but 
both littermate controls (n=11) and AAV-treated ARG1−/− animals (n=11) responded to 
acetate injection with a comparable (>20%) decline in the plasma glutamine concentration. 
Similarly littermate controls (n=11), showed a decline (>20%) of blood arginine; in contrast, 
acetate treatment evoked a slight increase (~3%) of blood arginine in AAV-treated ARG1−/− 
mice (n=11). Similarly citrulline declined in the littermate controls (n=11) and increased in 
AAV-treated mice (n=11). The AAV-treated animals (n=6) demonstrated hypoornithinemia 
compared to the littermates (n=11); circulating plasma ornithine in the AAV-treated 
ARG1−/− mice at baseline was only 57% of littermate controls. Plasma ornithine in the 
littermate controls demonstrated a decline of ~17% thirty minutes after acetate 
administration; however ornithine only declined ~4% in the AAV-treated mice after acetate 
administration.
Hepatocellular Arginase Activity and Ureagenesis
Our prior investigations6, 9 indicated that hepatic arginase expression declined with animal 
growth as AAV episomes were lost consequent to hepatocellular division. We examined 
hepatic arginase activity in littermate controls and AAV-treated ARG1−/− mice in these 
studies. Immunohistochemistry demonstrated scattered arginase-positive cells throughout 
the liver parenchyma (Figure 2 C, D) compared to littermate controls; no collagen 
deposition consistent with fibrosis was present. Arginase expression was widespread in the 
latter animals. Ureagenesis was examined in AAV-treated ARG1−/− mice (n=11) and 
compared to littermate controls (n=11) by [1-13C] acetate administration. The findings 
demonstrated that the rate of ureagenesis is about 3.3% of control animals (Figure 4).
Discussion
Urea is the major end-product of mammalian nitrogen metabolism. The arginase 1 single 
point mutation in our mouse model results in no residual enzyme activity in the liver. We 
showed previously that arginase 1 knockout mice were able to survive and have normal 
learning and cognitive function as adults with reduced hepatic enzyme activity after neonatal 
administration of an AAV vector expressing arginase 16–8. However in the studies 
conducted herein, we have demonstrated that the livers of the AAV-treated ARG1−/− mice 
weigh more than the littermate controls. Our group has previously demonstrated that 
hepatocytes from the ARG1−/− mice are two- to threefold larger than that of controls12 
suggesting that hepatocytes are undergoing hypertrophy and this may be why the organ 
weights from these animals were greater. The hepatocytes also have been demonstrated to 
contain a variety of intracytoplasmic inclusions, including large, well-defined, round or oval 
eosinophilic inclusions12.
A key question is how much hepatic arginase activity is needed to normalize ureagenesis 
and allow survival of knockout mice. We addressed this problem by utilizing the stable 
isotope method to measure in vivo flux through the urea cycle. Our extensive experience 
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with this approach has demonstrated its utility in human investigations11, 13–17. It is 
important to understand the relationship between flux and enzyme activity in order to apply 
gene transfer technology to human trials and has been employed in these studies to answer 
this question.
Elevated plasma glutamine, a finding common in most urea cycle disorders, also is increased 
in the AAV-treated ARG1−/− mice. This abnormality reflects the tendency to 
hyperammonemia in animals with a limited number of arginase expressing cells in the liver 
and elsewhere6, 8. These animals also are more vulnerable to administration of ammonium 
chloride, as previously demonstrated7. The administration of acetate to these animals and 
littermate controls caused a decline (~20%) of blood glutamine concentration, perhaps 
denoting an increase of N-acetylglutamate (synthesized from acetyl CoA and L-glutamate), 
an obligatory effector of carbamoyl phosphate synthetase 1, the initial step of the urea cycle. 
The lowered blood glutamine also could reflect a sudden release of insulin19.
Hepatic mitochondria convert CH313COO− to H13CO3− in the tricarboxylic acid cycle and 
then condense the latter with NH4 to carbamoyl phosphate, which mitochondria combine 
with ornithine to yield citrulline. In the littermate controls, we detect a decline of circulating 
ornithine of about 18% as it is consumed in the generation of citrulline. Progressing through 
the urea cycle, plasma citrulline and arginine concentrations also decline (here about 22% 
from baseline for both) as arginase acts on arginine to generate [13C] urea and also 
regenerate ornithine.
However, in the AAV-treated ARG1−/− mice a different biochemical picture emerges. 
Plasma arginine and citrulline levels are high because limited hepatic arginase enzymatic 
activity restricts regeneration of ornithine from arginine. Indeed, baseline ornithine is only 
about 50% of the value in controls. While plasma ornithine does decline with the 
administration of acetate as in the littermate controls, the magnitude is substantially less: 
only about 4% from baseline. Conversely and unlike the littermate controls, plasma arginine 
and citrulline concentrations increase slightly as, we speculate, that there is more flux into 
the proximal urea cycle due to acetate administration, likely due to the limited hepatic 
arginase activity. Thus the limited amount of arginase activity allows animal survival6, 
control of circulating ammonia, and development of a normal central nervous system7. 
However, the metabolic defect still is associated with increased in hepatic cell mass as seen 
in the AAV-treated ARG1−/− mice.
While the findings described may have important implications for arginase deficiency, they 
are not broadly applicable to other disorders of the urea cycle, particularly the proximal 
disorders. Studies conducted with the ornithine transcarbamoylase deficient (spf)20–21 and 
arginosuccinate synthetase deficient22 murine models demonstrate that the residual 
expression of enzyme in hepatocytes after AAV administration in the neonatal period are 
insufficient to prevent hyperammonemia and death. However, in the studies conducted 
herein the measurement of ureagenesis in these AAV-treated ARG1−/− mice has now 
allowed for an improved understanding of the relationship between the residual arginase 
activity and in vivo metabolic competency following a single dose of neonatal AAV 
expressing arginase 1. The findings from these studies have several important implications 
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and raise further questions. First with the loss of large numbers of episomal AAV vector 
DNA6, 8–9, a small amount remains that serves to provide minimal ureagenesis compared 
with controls. Our prior studies of a conditional knockout of arginase 1 supported this 
concept and demonstrated that arginase activity of as little as 9% of controls appeared to be 
necessary for survival in that adult-onset model23. The current studies suggest that <5% of 
control activity leads to normal development in neonatal onset arginase deficiency; however, 
the urea cycle still is not functioning normally and the animals do remain vulnerable to a 
nitrogen load7 but this is sufficient to provide long-term survival.
Second, plasma ornithine concentration remains low in the AAV-treated ARG1−/− mice. 
The question arises as to whether the administration of ornithine to AAV-treated ARG1−/− 
mice will improve function by increasing nitrogen flux into the urea cycle. Studies will 
commence to address this question; however we postulate that this treatment may improve 
proximal urea cycle function, thus leading to lower circulating plasma ammonia. However, 
this will not address the limited arginase capacity provided by the relatively small number of 
arginase-expressing hepatocytes. Furthermore, the urea cycle takes place in the periportal 
hepatocytes and expression of arginase in hepatocytes by AAV-based expression is 
heterogenous in its location.
A final question is whether an improvement in urea cycle function will occur with a second 
administration of AAV expressing arginase 1. Our previous studies have demonstrated that 
operational tolerance is established to transgene-encoded proteins with neonatal 
administration of AAV-expressing vectors in mice6, 10. Immunologic ignorance appears to 
be an important mechanism for lack of an immune response to AAV when administered in 
the neonatal period to mice (unpublished data); these findings and that of others22 suggest 
that these animals would benefit from readministration of AAV after adult organ size has 
been reached, typically by about 5–6 weeks of life9. As an associated decline in episomal 
copy number would be expected in the human liver (albeit over a longer period than the 
murine liver where the rate of doubling is much more rapid); such questions will be 
important to address as therapies for arginase deficiency and other metabolic disorders with 
AAV-based therapy are considered for clinical application.
Materials and Methods
Materials
Sodium [1-13C] acetate ([98.0 atom% excess) was purchased from Cambridge Isotope 
Laboratories (Woburn, MA, USA). Reagents for derivatization of urea and amino acids were 
from Pierce Chemical Co. (Rockford, IL, USA).
Mouse Procedures
The targeted ARG1 allele contains a deletion in exon 4 of the ARG1 gene and were 
generated12 and backcrossed to achieve a homogeneous NIH-Swiss strain background as 
described previously6. All mice were housed under specific pathogen-free conditions with 
food and water provided ad libitum. Mice were kept according to the National Institutes of 
Health guidelines and all experimental procedures were conducted in accordance with 
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guidelines for the care and use of research animals at our institution. Arginase-deficient 
newborn pups on the second day of life were injected with 1.0×1014 gc/kg of AAVrh10 
TBG-mArg1 diluted in pharmaceutical grade saline by the superficial facial vein. The 
injections were performed in a total volume of 50 µl. 10–12-week-old mice were studied. 
Mice were fed standard mouse chow (Labdiet/PMI Nutrition International, St. Louis, MO., 
[Picolab Rodent diet 20, Catalogue Number 5053]). At 8 am of the day of study, chow was 
removed. At 11 am baseline blood was collected followed by intraperitoneal administration 
of 1% [1-13C] acetate (5.4 µl/gram weight) prepared in sterile pharmaceutical grade saline in 
a total volume of 500 µl. Thirty minutes later blood was collected and the animals were 
euthanized. Plasma and serum was frozen immediately and stored at −80°C until analysis. 
Whole livers were removed and weighed.
PCR genotyping
Genomic DNA was prepared from tail tip by standard methods and genotyping by PCR was 
performed as previously described6.
Biochemical Analysis of Serum
The concentration of amino acids was determined by HPLC utilizing pre-column 
derivatization with o-phthalaldehyde as previously described24.
Ammonia Analysis of Serum
Ammonia was determined in serum samples by reductive amination of 2-oxoglutarate and 
oxidation of NADPH employing a commercial kit (Sigma-Aldrich, St. Louis, MO) using 10 
µl for each sample tested. Results are presented as mean ± SD.
Immunohistochemistry for Arginase Expression
Livers were removed from euthanized animals and placed in 4% paraformaldehyde for 18–
24 hours. Immunohistochemistry was performed as previously described6.
Sodium 1-13C Acetate Loading Study
The studies were performed in the morning after food was removed. Baseline samples of 
blood were collected as well as 30 minute samples. Specimens were centrifuged at 4° to 
isolate plasma. The measurement of [13C] urea was performed as previously described16 
with appropriate adjustment of volumes based on quantity of mouse plasma.
Statistical Analysis
Survival curves were computed in each group of mice using the Kaplan-Meier (KM) method 
and compared across groups using the log rank test. Calculations were made using software 
JMP PRO version 11 (SAS, Cary, NC). T test was utilized for other statistical analyses for 
other comparisons. P values of <0.05 were considered significant.
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Figure 1. Survival of ARG1−/− mice
Survival in days of untreated ARG1−/− mice (n=8), intravenous-injected rAAVrh10-co-
Arginase ARG1−/− mice (n=14), and untreated littermate controls (n=18). The ARG1−/− 
mice treated with AAVrh10-co-Arginase exhibited a marked improvement in survival when 
compared to that of the untreated ARG1−/− mice. (p=0.43 for treated compared with 
littermate controls and p<0.0001 when AAV-treated ARG1−/− mice or littermates were 
compared to untreated ARG1−/− mice.)
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Figure 2. Gross and microscopic examination of murine liver
On the left (A) is a liver from a littermate control animal at 4 months of age. On the right (B) 
is the liver from an AAV-treated ARG1−/− mouse demonstrating the typical appearance of 
this organ upon removal from the animal. Representative sections of arginase expression in 
(C) littermate controls and (D) AAV-treated ARG1−/− mice at 4 months of age are depicted. 
(Both microscopic images are at 100× magnification.)
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Figure 3. Plasma ammonia comparison between littermates and AAV-treated ARG1−/− mice
Plasma ammonia was measured after collecting blood at 4 months in both littermates (n=10) 
and in AAV-treated animals (n=9). The horizontal line is the box is the median and the 
horizontal line at the top of the box is the 75th percentile while the horizontal line at the 
bottom is the 25th percentile. The horizontal lines above and below the box represent the 
maximum and minimum values.
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Figure 4. Ureagenesis in stable adult AAV-ARG1−/− mice and littermate controls
[13C] urea was measured 30 minutes after administration of [1-13C] acetate. Adult AAV-
treated ARG1−/− mice (n=11) have ureagenesis, albeit at greatly reduced levels compared to 
littermates (n=11). Error bars represent standard deviation.
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Table 1
Urea Cycle Amino Acids in Study Groups
Littermate AAV-Treated Arg1−/− p value
Glutamine
Time 0 455.4 ± 121.5 921.0 ± 298.3 0.0001
Time 30 357 ± 75.0 680.0 ± 216.5 0.0001
% change −21.6 −26.2
Ornithine
Time 0 71.9 ± 36.9 35.8 ± 18.7 0.02
Time 30 59.2 ± 33.4 34.5 ± 30.9 0.32
% change −17.7 −3.8
Arginine
Time 0 198.3 ± 80.1 535.1 ± 129.3 4.30E-07
Time 30 154.6 ± 60.8 553.4 ± 122.2 5.30E-09
% change −22.1 3.4
Citrulline
Time 0 72.9 ± 24.5 132.0 ± 39.0 0.0004
Time 30 57.0 ± 20.9 143.7 ± 44.2 0.00001
% change −21.8 8.9
Data are presented as nmol/ml as mean ± SD.
Gene Ther. Author manuscript; available in PMC 2015 August 01.
